Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 8/2006

01-08-2006

The Role of Whole-Body Fluorine-18-FDG Positron Emission Tomography in the Detection of Recurrence in Symptomatic Patients with Stages II and III Breast Cancer

Authors: Ryan M. Wolfort, MD, Benjamin D.L. Li, MD, Lester W. Johnson, MD, Richard H. Turnage, MD, David Lilien, MD, Fred Ampil, MD, Gary Burton, MD, Quyen D. Chu, MD

Published in: World Journal of Surgery | Issue 8/2006

Login to get access

Abstract

Background

The role of whole-body fluorine-18-FDG positron emission tomography (FDG-PET) as an adjunct localize recurrence in stages II and III breast cancer patients who present with clinical suspicion for recurrence is not well established. We report our experience in such a patient population.

Methods

A retrospective review of all patients with stages II and III breast cancer who had a whole-body FDG-PET scan was performed.

Results

Of the 23 patients who fit the criteria, 9 had stage II and 14 had stage III breast cancer. Overall sensitivity, specificity, and accuracy were 81%, 100%, and 87%, respectively. Positive and negative predictive values for stages II and III were 100% and 83%, respectively, and 100% and 50%, respectively. FDG-PET detected two recurrences that were missed by conventional imagings, but such recurrences were local and amenable for biopsy.

Conclusions

In patients with stages II and III breast cancer who present with a suspicion for recurrent disease, a whole-body FDG-PET scan may be a useful adjunct in the evaluation of recurrence. However, its added benefit over conventional imaging should be questioned.
Literature
1.
Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305–332PubMed
2.
Quon A, Gambhir SS. FDG-PET and beyond: Molecular breast cancer imaging. J Clin Oncol 2005;23:1664–1673PubMedCrossRef
3.
Danforth DN Jr, Aloj L, Carrasquillo JA, et al. The role of 18 F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002;75:135–146PubMedCrossRef
4.
Schelling M, Avril N, Nohrig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–1695PubMed
5.
Vranjevesic D, Filmont JE, Meta J, et al. Whole body (18)F-FDG PET and conventional imaging for predicting the outcome of previously treated breast cancer patients. J Nucl Med 2002;43:325–329
6.
Keyes JW. SUV: Standard uptakes or silly useless values? J Nucl Med 1995;36:1836–1839PubMed
7.
8.
Baslaim MM, Bakheet SM, Bakheet R, et al. 18-fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg 2003;27:1099–1104PubMedCrossRef
9.
Siggelkow W, Zimny M, Faridi A. The value of positron emission in the follow-up for breast cancer. Anticancer Res 2003;23:1859–1860PubMed
10.
Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of tumor recurrence in the follow up of patients with breast carcinoma: comparison to conventional imaging. Invest Radiol 2003;38:250–256PubMedCrossRef
11.
Kamel EM, Wyss MT, Fehr MK, et al. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003;129:147–153PubMed
12.
Bender H, Kirst J, Palmedo H, et al. Value of 18Fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997;17:1687–1692PubMed
13.
Kim TS, Moon WK, Lee DS, et al. Fluorodeoxyglucose positron emission for detection of recurrent or metastatic breast cancer. World J Surg 2001;25:829–834PubMedCrossRef
14.
Moon DH, Maddahi J, Silverman DHS, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431–435PubMed
15.
Garb JL. Understanding medical research. A practitioner’s guide. Little, Brown & Company, New York 1996
16.
Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375PubMed
17.
Bunker SR, Dunleavy CB. Fusion changes patient management with PET & CT. J Clin Oncol 2004;22:702
Metadata
Title
The Role of Whole-Body Fluorine-18-FDG Positron Emission Tomography in the Detection of Recurrence in Symptomatic Patients with Stages II and III Breast Cancer
Authors
Ryan M. Wolfort, MD
Benjamin D.L. Li, MD
Lester W. Johnson, MD
Richard H. Turnage, MD
David Lilien, MD
Fred Ampil, MD
Gary Burton, MD
Quyen D. Chu, MD
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 8/2006
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-0207-6

Other articles of this Issue 8/2006

World Journal of Surgery 8/2006 Go to the issue

OriginalPaper

Incurable Stenosing Colorectal Carcinoma: Endoscopic Stent Implantation or Palliative Surgery?

OriginalPaper

Covering the Percutaneous Endoscopic Gastrostomy (PEG) Tube Prevents Peristomal Infection

OriginalPaper

Specific Targeting of Pancreatic Islet Cells In Vivo by Insulin-Promoter-Driven Adenoviral Conjugated Reporter Genes

OriginalPaper

Hand-assisted Laparoscopic Splenectomy and Devascularization of the Upper Stomach in the Management of Gastric Varices

OriginalPaper

Biomedical Industrial Sponsorship and Its Impact on the Medical Literature

EDITORIAL PERSPECTIVES

The Journal of the Future Is Here Today